ERBB2 and breast cancer: AZD1775 monotherapy has also been reported to extend the survival of pancreatic (159), NSCLC (160) and glioma (161) mouse xenografts in vivo. In HER-2 positive breast cancer, AZD1775 has shown remarkable anticancer effects by overcoming anti-HER2 agent trastuzumab resistance through the initiation of apoptosis and G2/M arrest in breast cancer cells in vitro (162).